Price cuts and broader reach put Perrigo’s Nasonex 24HR front and center

Perrigo is leaning on its over-the-counter allergy spray Nasonex 24HR to capture value-conscious US shoppers, combining prescription-level dosing with aggressive retail pricing and wide availability at chains like CVS, Walgreens and Walmart.

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 5:00 PM ET. Details in the imprint.

In the crowded allergy aisle, Perrigo’s Nasonex 24HR is quietly positioning itself as a high-strength, lower-cost alternative to prescription nasal sprays, with broad US retail availability and an over-the-counter dosing of 50 micrograms of mometasone furoate per spray. The OTC product, approved by the FDA as a nasal allergy treatment for patients 12 and older, offers once-daily symptom relief for seasonal and perennial allergic rhinitis and is now widely stocked at major US chains at price points that undercut many legacy prescription brands. FDA drug information for Nasonex 24HR details the active ingredient and labeled uses.

What Nasonex 24HR offers value-seeking allergy sufferers

Nasonex 24HR is an over-the-counter intranasal corticosteroid spray that uses mometasone furoate, a molecule long used in prescription Nasonex formulations, to reduce inflammation in the nasal passages and ease symptoms like congestion, sneezing and runny nose. Each actuation delivers 50 mcg of mometasone furoate from a pump designed for once-daily dosing, with packaging that typically provides 120 metered sprays per bottle, enough for up to 60 days of use at the standard two-sprays-per-nostril daily regimen for adults and adolescents. According to Perrigo’s US consumer-health portfolio materials, the brand sits alongside other OTC mainstays such as store-brand antihistamines, but keeps the branded Nasonex name to signal its prescription heritage and steroid-based mechanism of action.

The product is targeted primarily at adults and children 12 years and older who suffer from seasonal allergies like hay fever as well as year-round allergic rhinitis triggered by dust mites, pet dander and other indoor allergens. Typical retail listings show Nasonex 24HR priced roughly in line with or slightly below other branded OTC nasal steroids such as Flonase and Rhinocort, while offering comparable 24-hour relief when used regularly as directed. Major US retailers, including CVS, Walgreens, Walmart and large supermarket chains, carry the spray both in-store and online, with Perrigo using a mix of branded packaging and store-shelf promotion to highlight its 24-hour efficacy claim and prescription-strength background. Recent retail circulars and online product pages emphasize multi-pack offers and loyalty-program discounts, aiming squarely at cost-sensitive families managing chronic allergy symptoms.

Behind the shelf, Nasonex 24HR reflects Perrigo’s broader strategy of converting established prescription medicines into consumer-facing OTC brands the company can distribute at scale. The group has spent years building out its self-care portfolio, and Nasonex 24HR now sits within a respiratory and allergy segment that also includes generic/store-brand versions of oral antihistamines and decongestants in North America and Europe. In recent investor communications, Perrigo has highlighted its ability to leverage large-scale manufacturing and partnerships with mass retailers to win share from both brand-name and generic competitors in categories like allergy care, using products such as Nasonex 24HR as proof points for its “self-care” positioning. A recent annual report from Perrigo underlines how branded OTC launches in allergy and upper-respiratory products contributed to its consumer self-care revenue mix. Perrigo’s latest Form 10-K describes the company’s strategy in OTC upper-respiratory and allergy products, including nasal sprays.

As an intranasal corticosteroid, Nasonex 24HR is designed for regular, preventive use rather than on-demand symptom chasing: clinical guidance generally indicates that this class of spray can take several days of consistent use to reach full effect, but then maintains relief for 24 hours per dose. FDA-label information emphasizes proper priming of the pump, daily adherence and avoidance of exceeding the recommended dose, particularly over longer periods, given class warnings such as potential nasal irritation and, rarely, effects on intraocular pressure or growth in children. Pharmacies typically shelve Nasonex 24HR alongside antihistamine sprays and saline rinses, with box labeling highlighting that it is fragrance free and non-addictive, differentiating it from older decongestant sprays that carry rebound-congestion risks if overused.

Perrigo has progressively expanded Nasonex 24HR’s distribution since gaining rights to the OTC formulation, and the brand contributes to the company’s North American consumer self-care segment, a core revenue driver reported in its recent filings. Within that segment, nasal allergy and upper-respiratory products form one of several pillars alongside gastrointestinal, dermatological and women’s health offerings, giving Perrigo recurring, seasonal revenue streams in markets like the US where allergy prevalence is high. Shares of Perrigo Company PLC (IE00BGH1M568) traded on the NYSE at $10.98 at the close on 06/12/2026, according to recent market data from Google Finance. Google Finance’s PRGO quote page shows the latest traded price and recent performance.

Nasonex 24HR in brief: key product facts

• Product: Nasonex 24HR (over-the-counter nasal spray)
• Manufacturer: Perrigo Company PLC
• Category: Flagship/Bestseller OTC allergy treatment
• Launch date: OTC formulation commercialized in the US after FDA prescription-to-OTC switch (Perrigo messaging points to mid-2020s rollout)
• MSRP / Price: Typically priced in the mid-to-upper teens in USD for a 120-spray bottle at large US retailers; promotional pricing and multi-pack discounts can reduce the effective cost per day
• Availability: Widely available in the US at pharmacies, mass retailers and online channels, including CVS, Walgreens, Walmart and supermarket chains
• Target audience: Adults and children 12+ with seasonal or perennial allergic rhinitis seeking 24-hour nasal-spray relief
• Key differentiator / USP: Prescription-derived intranasal corticosteroid (mometasone furoate) offered as an OTC, once-daily spray with broad US retail distribution

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.